2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2369

Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Abstract Number: 2370

Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Abstract Number: 2371

Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database
Abstract Number: 2372

Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry
Abstract Number: 2373

Two Decades of Changes in RA Treatment and Disease Outcomes from the United States
Abstract Number: 2374

MRI of the Wrist in Early Rheumatoid Arthritis After 1-year Treat-to-target Strategy
Abstract Number: 2375

Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports
Abstract Number: 2376

Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis
Abstract Number: 2377

Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Abstract Number: 2378

Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA
Abstract Number: 2379

High Initial Methotrexate Dose Is Not Associated with an Increased Risk of Liver Toxicity in Korean Patients with Rheumatoid Arthritis
Abstract Number: 2380

Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome
Abstract Number: 2381

Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA
Abstract Number: 2382

Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis
Abstract Number: 2383

Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].